PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines
Authors:
Open Access
- 1 September 2012
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 20 (9) , 1800-1809
Abstract
No abstract availableKeywords
Funding Information
- Korea National Institute of Health
- Bill and Melinda Gates Foundation
- California HIV/AIDS Research Program
This publication has 40 references indexed in Scilit:
- Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cellsProceedings of the National Academy of Sciences, 2011
- HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cellsProceedings of the National Academy of Sciences, 2009
- Enhancing SIV-specific immunity in vivo by PD-1 blockadeNature, 2008
- Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus MonkeysJournal of Virology, 2008
- Enhancing therapeutic vaccination by blocking PD-1–mediated inhibitory signals during chronic infectionJournal of Experimental Medicine, 2008
- Engineered lentivector targeting of dendritic cells for in vivo immunizationNature Biotechnology, 2008
- DC-based cancer vaccinesJournal of Clinical Investigation, 2007
- Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus ChallengeJournal of Virology, 2006
- PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infectionJournal of Experimental Medicine, 2006
- Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunityNature Reviews Immunology, 2004